GLSI Stock Forecast: Greenwich LifeSciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$19
−1.87% on the day

The median 12-month analyst price target for Greenwich LifeSciences, Inc. is $58. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$290.5M
Ticker Nerd rank
53/ 100
Median analyst target
$58
Analysts covering
2
Revenue$0.0
Operating income−$4.0M
Net income−$3.9M
Free cash flow−$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+30.0%
1M
+19.6%
YTD
−7.6%
1Y
+138.0%
From 52W high
−42.1%
From 52W low
+147.4%
$8
$34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Greenwich LifeSciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
53/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
91
Momentum
80
Accruals
63
Volatility
63
Growth
43
Issuance
42
Revisions
32
Quality
14

Value (91): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Quality (14): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GLSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GLSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26GLSIHigh $70Median $58Low $45

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$45
Low
$58
Median
$70
High
Recent analyst actionsNewest first

Of the 13 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Nov 2026HC Wainwright & Co.MaintainsBuy$69 → $70
21 July 2026HC Wainwright & Co.MaintainsBuy$50 → $69
30 Dec 2025HC Wainwright & Co.MaintainsBuy$39 → $50
21 Apr 2025HC Wainwright & Co.MaintainsBuy—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
23 Aug 2024HC Wainwright & Co.MaintainsBuy—
22 May 2024HC Wainwright & Co.ReiteratesBuy—
28 Feb 2024HC Wainwright & Co.ReiteratesBuy—
20 Feb 2024HC Wainwright & Co.MaintainsBuy—
10 Apr 2023HC Wainwright & Co.ReiteratesBuy—
1 Sept 2021HC Wainwright & Co.InitiatesBuy—
27 Jan 2021Aegis CapitalInitiatesBuy—
26 Jan 2021Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GLSI.

Market Radar

This page is one stock. Monday covers all of them.

GLSI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GLSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Greenwich LifeSciences, Inc. returned +138.0% against +6.9% for the S&P 500, dividends included.

GLSI vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Jan 26Apr 26Jul 26Oct 26GLSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GLSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
88.4×

Cheaper than 1% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−11218.1%

Higher than 1% of US stocks

Return on assets
−319.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Greenwich LifeSciences, Inc. has a market value of $290.5M and an enterprise value of $284.6M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$21.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$12.5M.

  • Shares outstanding: 14.7M.

  • Greenwich LifeSciences, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

GLSI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GLSIGreenwich LifeSciences, Inc.$290.5M53
FULCFulcrum Therapeutics, Inc.$281.5M35
BNTCBenitec Biopharma, Inc.$285.9M39
RLMDRelmada Therapeutics, Inc.$274.8M55
EVMNEvommune, Inc.$291.1M11
GALTGalectin Therapeutics, Inc.$271.3M82
NAUTNautilus Biotechnology, Inc.$269.4M70

Take a look at GLSI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Greenwich LifeSciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GLSI

What is the GLSI stock price forecast for 2026-2027?

The median 12-month analyst price target for Greenwich LifeSciences, Inc. is $58, with estimates ranging from $45 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GLSI stock a buy right now?

Of the 2 analysts covering Greenwich LifeSciences, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Greenwich LifeSciences, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GLSI?

As at 21 Nov 2026, Greenwich LifeSciences, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (91 of 100).

Will GLSI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $58, and Ticker Nerd's factor model ranks Greenwich LifeSciences, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GLSI stock forecast for 2030?

No analyst covering Greenwich LifeSciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $45 to $70 over the next 12 months.

How has GLSI stock performed over the past year?

Greenwich LifeSciences, Inc. returned +138.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Greenwich LifeSciences, Inc. do?

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its primary program centers on GP2, an investigational peptide-based immunotherapy designed to help prevent breast cancer recurrence after surgery.

Company

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its primary program centers on GP2, an investigational peptide-based immunotherapy designed to help prevent breast cancer recurrence after surgery. The company’s research and clinical activities are concentrated on advancing cancer vaccines and immune-based treatments that target HER2-related disease, a major area in oncology where precision therapies play an important role. Greenwich LifeSciences operates as a biotechnology developer rather than a commercial drug producer, with its current work centered on clinical evaluation, safety, and efficacy of its lead candidates. Based in Stafford, Texas, Greenwich LifeSciences is positioned within the broader life sciences sector as a specialized company addressing unmet needs in post-treatment breast cancer care.

CEO Mr. Snehal S. Patel · 4 employees · United States · https://greenwichlifesciences.com